Dr. Cavalcante reports compensation for speaker´s bureau and honoraria from Gencell Pharma,

Libbs, Pfizer and Roche. Also, Dr. Cavalcante reported serving on the advisory board for MSD,

Roche, and Pfizer. Dr. Amorim participated in advisory boards, received honoraria, and was

invited by Roche to medical conferences. Dr. Ribeiro reports compensation for speaker´s bureau

and honoraria from Roche. Dra. Rosa reported serving on consulting and advisory board for

Amgen, AstraZeneca, Dr. Reddy, Eisai, GSK, Libbs, Lilly, Novartis, Pfizer, Roche, Sanofi, Teva,

United Medical, and Zodiac. No other disclosures were reported.

All authors contributed to writing the article and were approved to submit it for publication. In addition, the authors thank Dr. Alexandre Ferreira Oliveira, Dr. Reitan Ribeiro, and Dr. Ruffo Freitas-Junior for their review and inputs. CoreBox Medical Communications provided medical writing assistance.

 

1.            Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2021.

2.            Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA: a Cancer Journal for Clinicians. 2021;71(1):7-33.

3.            Aguiar S, Baiocchi G, Duprat JP, et al. Value of preoperative testing for SARS-CoV-2 for elective surgeries in a cancer center during the peak of pandemic in Brazil. Journal of Surgical Oncology. 2020;122(7):1293-1295. doi:https://doi.org/10.1002/jso.26146

4.            Cavalcante FP, Novita GG, Millen EC, et al. Management of early breast cancer during the COVID-19 pandemic in Brazil. Breast Cancer Res Treat. 2020;184(2):637-647. doi:10.1007/s10549-020-05877-y

5.            Papautsky EL, Hamlish T. Patient-reported treatment delays in breast cancer care during the COVID-19 pandemic. Breast Cancer Res Treat. 2020;184(1):249-254. doi:10.1007/s10549-020-05828-7

6.            Kaufman HW, Chen Z, Niles J, Fesko Y. Changes in the Number of US Patients With Newly Identified Cancer Before and During the Coronavirus Disease 2019 (COVID-19) Pandemic. JAMA Network Open. 2020;3(8):e2017267-e2017267. doi:10.1001/jamanetworkopen.2020.17267

7.            Czajka ML, Pfeifer C. Breast Cancer Surgery. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2020. http://www.ncbi.nlm.nih.gov/books/NBK553076/. Accessed January 13, 2021.

8.            Bartlett DL, Howe JR, Chang G, et al. Management of Cancer Surgery Cases During the COVID-19 Pandemic: Considerations. Ann Surg Oncol. 2020;27(6):1717-1720. doi:10.1245/s10434-020-08461-2

9.            American College of Surgeons. COVID-19 Guidelines for Triage of Breast Cancer Patients.https://www.facs.org/covid-19/clinical-guidance/elective-case/breast-cancer. Accessed January 15, 2021.

10.         Pryor A. SAGES and EAES recommendations regarding surgical response to COVID-19 crisis.https://www.sages.org/recommendations-surgical-response-covid-19. Published March 30, 2020. Accessed January 15, 2021.

11.         Hwang ES, Balch CM, Balch GC, et al. Surgical Oncologists and the COVID-19 Pandemic: Guiding Cancer Patients Effectively through Turbulence and Change. Ann Surg Oncol. 2020;27(8):2600-2613. doi:10.1245/s10434-020-08673-6

12.         Ministério da Saúde. Brasil. Coronavírus Brasil. https://covid.saude.gov.br/. Published 2021. Accessed June 7, 2021.

13.         National Comprehensive Cancer Network (NCCN). Breast Cancer - Version 1.2021 - January 15, 2021. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed January 15, 2021.

14.         Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of Oncology. 2019;30(8):1194-1220. doi:10.1093/annonc/mdz173

15.         National Institute for Health and Care Excellence (NICE). COVID-19 rapid guideline: arranging planned care in hospitals and diagnostic services: NICE guideline [NG179].https://www.nice.org.uk/guidance/ng179. Accessed April 14, 2021.

16.         Ribeiro R, Wainstein AJA, de Castro Ribeiro HS, Pinheiro RN, Oliveira AF. Perioperative Cancer Care in the Context of Limited Resources during the COVID-19 Pandemic: Brazilian Society of Surgical Oncology Recommendations. Ann Surg Oncol. September 2020. doi:10.1245/s10434-020-09098-x

17.         Dinnes J, Deeks JJ, Adriano A, et al. Rapid, point‐of‐care antigen and molecular‐based tests for diagnosis of SARS‐CoV‐2 infection. Cochrane Database of Systematic Reviews. 2020;(8). doi:10.1002/14651858.CD013705

18.         World Health Organization (WHO). Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays. https://www.who.int/publications/i/item/antigen-detection-in-the-diagnosis-of-sars-cov-2infection-using-rapid-immunoassays. Accessed April 16, 2021.

19.         Centers for Disease Control and Prevention (CDC). Using Antibody Tests for COVID-19.https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests.html. Accessed April 14, 2021.

20.         World Health Organization (WHO). Advice on the use of point-of-care immunodiagnostic tests for COVID-19: scientific brief. https://www.who.int/news-room/commentaries/detail/advice-on-the-use-of-point-of-care-immunodiagnostic-tests-for-covid-19. Published 2020. Accessed April 16, 2021.

21.         Centers for Disease Control and Prevention (CDC). Sequence for putting on personal protective equipment (PPE). https://www.cdc.gov/hai/pdfs/ppe/ppe-sequence.pdf. Accessed January 15, 2021.

22.         Centers for Disease Control and Prevention (CDC). Clinical Questions about COVID-19: Questions and Answers.https://www.cdc.gov/coronavirus/2019-ncov/hcp/faq.html. Accessed April 14, 2021.

23.         Centers for Disease Control and Prevention (CDC). Interim Guidelines for COVID-19 Antibody Testing.https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html. Accessed April 14, 2021.

24.         European Society for Medical Oncology (ESMO). ESMO Management and Treatment Adapted Recommendations in the COVID-19 Era: Breast Cancer.https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/breast-cancer-in-the-covid-19-era. Accessed January 15, 2021.

25.         Centers for Disease Control and Prevention (CDC). Interim U.S. Guidance for Risk Assessment and Work Restrictions for Healthcare Personnel with Potential Exposure to SARS-CoV-2.https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-risk-assesment-hcp.html. Accessed April 14, 2021.

26.         National Comprehensive Cancer Network (NCCN). Recommendations of the NCCN COVID-19 Vaccination Advisory Committee. https://www.nccn.org/covid-19. Accessed April 16, 2021.

27.         European Society for Medical Oncology (ESMO). ESMO Statements for vaccination against COVID-19 in patients with cancer.https://www.esmo.org/covid-19-and-cancer/covid-19-vaccination. Accessed April 16, 2021.

28.         Bitterman R, Eliakim-Raz N, Vinograd I, Zalmanovici Trestioreanu A, Leibovici L, Paul M. Influenza vaccines in immunosuppressed adults with cancer. Cochrane Database Syst Rev. 2018;2:CD008983. doi:10.1002/14651858.CD008983.pub3

29.         Centers for Disease Control and Prevention (CDC). Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States.https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html. Accessed April 14, 2021.

30.         Centers for Disease Control and Prevention (CDC). Updated Healthcare Infection Prevention and Control Recommendations in Response to COVID-19 Vaccination.https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control-after-vaccination.html. Accessed April 14, 2021.

31.         Centers for Disease Control and Prevention (CDC). Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events: Moderna COVID-19 Vaccine.https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/reactogenicity.html. Accessed April 14, 2021.

32.         Simon SD, Bines J, Werutsky G, et al. Characteristics and prognosis of stage I-III breast cancer subtypes in Brazil: The AMAZONA retrospective cohort study. Breast. 2019;44:113-119. doi:10.1016/j.breast.2019.01.008

33.         Dietz JR, Moran MS, Isakoff SJ, et al. Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium. Breast Cancer Res Treat. April 2020:1-11. doi:10.1007/s10549-020-05644-z

34.         Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Annals of Oncology. 2015;26(8):1533-1546. doi:10.1093/annonc/mdv221

35.         Marcus A, Gowen BG, Thompson TW, et al. Recognition of tumors by the innate immune system and natural killer cells. Advances in immunology. 2014;122:91-128.

36.         Cai G, Gao Y, Zeng S, et al. Immunological alternation in COVID-19 patients with cancer and its implications on mortality. Oncoimmunology. 2021;10(1):1854424. doi:10.1080/2162402X.2020.1854424

37.         Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-280.e8. doi:10.1016/j.cell.2020.02.052

38.         Thevarajan I, Nguyen THO, Koutsakos M, et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nature Medicine. 2020;26(4):453-455. doi:10.1038/s41591-020-0819-2

39.         Han HJ, Nwagwu C, Anyim O, Ekweremadu C, Kim S. COVID-19 and cancer: From basic mechanisms to vaccine development using nanotechnology. Int Immunopharmacol. 2021;90:107247. doi:10.1016/j.intimp.2020.107247

40.         Ferreira CE, Bonvehi PE, Torre JCG de la, Sáenz-Flor KV, Condino-Neto A. Algorithms for testing COVID-19 focused on use of RT-PCR and high-affinity serological testing: A consensus statement from a panel of Latin American experts. International Journal of Infectious Diseases. 2021;103:260-267. doi:10.1016/j.ijid.2020.11.173

41.         Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2. JAMA. 2020;323(22):2249. doi:10.1001/jama.2020.8259

42.         Mattioli IA, Hassan A, Oliveira ON, Crespilho FN. On the Challenges for the Diagnosis of SARS-CoV-2 Based on a Review of Current Methodologies. ACS Sens. December 2020. doi:10.1021/acssensors.0c01382

43.         Li Y, Yao L, Li J, et al. Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19. Journal of Medical Virology. 2020;92(7):903-908. doi:https://doi.org/10.1002/jmv.25786

44.         Pray IW. Performance of an Antigen-Based Test for Asymptomatic and Symptomatic SARS-CoV-2 Testing at Two University Campuses — Wisconsin, September–October 2020. MMWR Morb Mortal Wkly Rep. 2021;69. doi:10.15585/mmwr.mm695152a3

45.         Cheng MP, Yansouni CP, Basta NE, et al. Serodiagnostics for Severe Acute Respiratory Syndrome–Related Coronavirus-2. Ann Intern Med. June 2020. doi:10.7326/M20-2854

46.         Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study. Anaesthesia. n/a(n/a). doi:https://doi.org/10.1111/anae.15458

47.         Mills GH. Respiratory complications of anaesthesia. Anaesthesia. 2018;73(S1):25-33. doi:https://doi.org/10.1111/anae.14137

48.         Kantor O, Wakeman M, Weiss A, et al. Axillary Management After Neoadjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer. Ann Surg Oncol. August 2020. doi:10.1245/s10434-020-09073-6

49.         Kantor O, Pesce C, Liederbach E, Wang C-H, Winchester DJ, Yao K. Are the ACOSOG Z0011 trial findings being applied to breast cancer patients undergoing neoadjuvant chemotherapy? The breast journal. 2017;23(5):554-562.

50.         Giuliano AE, Ballman KV, McCall L, et al. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA. 2017;318(10):918-926. doi:10.1001/jama.2017.11470

51.         Moo T-A, Edelweiss M, Hajiyeva S, et al. Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection? Ann Surg Oncol. 2018;25(6):1488-1494. doi:10.1245/s10434-018-6429-2

52.         Moo T-A, Pawloski KR, Flynn J, et al. Is Residual Nodal Disease at Axillary Dissection Associated with Tumor Subtype in Patients with Low Volume Sentinel Node Metastasis After Neoadjuvant Chemotherapy? Ann Surg Oncol. April 2021. doi:10.1245/s10434-021-09910-2

53.         Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy. 2021. https://clinicaltrials.gov/ct2/show/NCT01901094.

54.         Almahariq MF, Levitin R, Quinn TJ, et al. Omission of Axillary Lymph Node Dissection is Associated with Inferior Survival in Breast Cancer Patients with Residual N1 Nodal Disease Following Neoadjuvant Chemotherapy. Ann Surg Oncol. 2021;28(2):930-940. doi:10.1245/s10434-020-08928-2

55.         Hammond JB, Parnall TH, Scott DW, et al. Gauging the efficacy of neoadjuvant endocrine therapy in breast cancer patients with known axillary disease. J Surg Oncol. June 2020. doi:10.1002/jso.26047

56.         Bi Z, Liu J, Chen P, et al. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla. Breast Cancer. 2019;26(3):373-377. doi:10.1007/s12282-018-00934-3

57.         Tuttle TM, Burke EE. Bilateral Mastectomy: Doubling Down on Complications? Ann Surg Oncol. 2015;22(11):3407-3408. doi:10.1245/s10434-015-4629-6

58.         Valero MG, Muhsen S, Moo T-A, et al. Increase in Utilization of Nipple-Sparing Mastectomy for Breast Cancer: Indications, Complications, and Oncologic Outcomes. Ann Surg Oncol. 2020;27(2):344-351. doi:10.1245/s10434-019-07948-x

59.         Angarita FA, Acuna SA, Cordeiro E, et al. Thirty-day postoperative morbidity and mortality in elderly women with breast cancer: an analysis of the NSQIP database. Breast Cancer Res Treat. 2018;170(2):373-379. doi:10.1007/s10549-018-4747-5

60.         O’Connell RL, Baker E, Trickey A, et al. Current practice and short-term outcomes of therapeutic mammaplasty in the international TeaM multicentre prospective cohort study. Br J Surg. 2018;105(13):1778-1792. doi:10.1002/bjs.10959

61.         Cavalcante FP, Novita GG, Millen EC, Zerwes FP, Freitas Junior R. Breast reconstruction and coronavirus pandemic. J Plast Reconstr Aesthet Surg. 2021;74(3):644-710. doi:10.1016/j.bjps.2020.08.103

62.         Desai A, Gainor JF, Hegde A, et al. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nature Reviews Clinical Oncology. March 2021:1-7. doi:10.1038/s41571-021-00487-z

63.         Corti C, Crimini E, Tarantino P, et al. Current Perspectives: SARS-CoV-2 vaccines for cancer patients: a call to action. European Journal of Cancer. February 2021:S0959804921000824. doi:10.1016/j.ejca.2021.01.046

64.         Marra A, Generali DG, Zagami P, et al. LBA77 Anti-SARS-CoV-2 antibody response in patients with cancer and oncology healthcare workers: A multicenter, prospective study. Annals of Oncology. 2020;31:S1206. doi:10.1016/j.annonc.2020.08.2318

65.         Miraglia JL, Abdala E, Hoff PM, et al. Immunogenicity and Reactogenicity of 2009 Influenza A (H1N1) Inactivated Monovalent Non-Adjuvanted Vaccine in Elderly and Immunocompromised Patients. PLOS ONE. 2011;6(11):e27214. doi:10.1371/journal.pone.0027214

66.         Brydak LB, Guzy J, Starzyk J, Machała M, Góźdź SS. Humoral immune response after vaccination against influenza in patients with breast cancer. Support Care Cancer. 2001;9(1):65-68. doi:10.1007/s005200000186

67.         Ward EM, Flowers CR, Gansler T, Omer SB, Bednarczyk RA. The importance of immunization in cancer prevention, treatment, and survivorship. CA: a cancer journal for clinicians. 2017;67(5):398-410.

68.         Loulergue P, Alexandre J, Iurisci I, et al. Low immunogenicity of seasonal trivalent influenza vaccine among patients receiving docetaxel for a solid tumour: results of a prospective pilot study. British Journal of Cancer. 2011;104(11):1670-1674. doi:10.1038/bjc.2011.142

69.         Grimm L, Destounis S, Dogan B, Nicholson B, Dontchos B, Sonnenblick E. SBI Recommendations for the Management of Axillary Adenopathy in Patients with Recent COVID-19 Vaccination. :3.

70.         Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events: Moderna COVID-19 Vaccine | CDC. https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/reactogenicity.html. Published February 19, 2021. Accessed February 26, 2021.

71.         Edmonds CE, Zuckerman SP, Conant EF. Management of Unilateral Axillary Lymphadenopathy Detected on Breast MRI in the Era of Coronavirus Disease (COVID-19) Vaccination. American Journal of Roentgenology. February 2021:AJR.21.25604. doi:10.2214/AJR.21.25604

72.         Thakkar A, Pradhan K, Jindal S, et al. Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy. Nature Cancer. March 2021:1-8. doi:10.1038/s43018-021-00191-y